David Schwartz to Reveal XRP Ledger Future at Ripple Swell 2026 
FDA Investigates New Cyclospora Outbreak as U.S. Cases Continue to Rise 
France to Release 10 Million Barrels of Diesel to Ease Fuel Prices 
Illinois Delays Crypto Tax Law Until July 2027 
U.S. Issues Cuba Health Alert as Illnesses Rise 
Samsung Q3 Profit Hits Record High on AI Memory Demand 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Kalshi Wins CFTC Approval for S&P 500 Perpetual Futures 
New Mexico Measles Outbreak Cost Reached $5.4 Million, Study Finds 
3 clinical-grade skincare creams you really shouldn’t buy online 
Circle Stock Falls 4% as Crypto Selloff Overshadows SAP Pay Expansion 
UK Sanctions Crypto Exchanges Linked to Russia 
Broadcom, Oracle and SpaceX Seek Billions in Private Debt for AI Expansion 
Australia Probes Flydubai Co-Pilot’s Links After FZ1073 Hijack Attempt 
Levi Strauss Beats Q3 Profit Estimates, Raises 2026 Outlook 
New York Declares Measles Disaster Emergency as Cases Surge 
Add as a preferred source on Google
The U.S. Food and Drug Administration (FDA) has authorized the marketing of six on! PLUS nicotine pouch products owned by Altria Group, marking the first approvals granted under the agency’s new pilot program designed to accelerate the review of certain tobacco-related products. The decision represents a significant milestone for the growing nicotine pouch market in the United States.
According to the FDA, the authorization applies specifically to six on! PLUS nicotine pouches manufactured by Helix Innovations LLC, a joint venture associated with Altria’s global on! PLUS portfolio. Altria submitted its premarket tobacco product applications for these products in June 2024, and the FDA cleared them under the pilot initiative launched in September to help streamline regulatory reviews.
The newly authorized on! PLUS nicotine pouches are available in mint, tobacco, and wintergreen flavors, with nicotine strengths of 6 mg and 9 mg. These products are now legally permitted for sale to adults in the U.S. The FDA emphasized that its decision was based on scientific evidence showing that the pouches contain lower levels of harmful chemicals compared to other smokeless tobacco products, which may translate into a reduced risk of cancer and other serious health conditions. The authorization is limited strictly to the approved products and does not extend to other Helix Innovations offerings.
Nicotine pouches are placed under the lip and do not involve combustion, inhalation, or the presence of tobacco leaf. As a result, they are widely viewed as among the lowest-risk alternatives to traditional smoking. This category has become the fastest-growing segment in the U.S. tobacco market as consumers increasingly seek smoke-free options.
Earlier in 2025, the FDA authorized 20 Zyn nicotine pouch products owned by Philip Morris International, making them the first in this category to receive U.S. market approval after a review process that lasted more than five years.
Following the FDA decision, Altria announced that on! PLUS will resume taking new retail orders in Florida, North Carolina, and Texas, as well as through e-commerce channels. While regulators continue to stress that nicotine products are intended only for adults, public health officials note that nicotine exposure during adolescence can negatively affect brain development related to attention, learning, mood, and impulse control.
